However, a meta-analysis by Evangelista et al. demonstrated that PSMA PET/MRI outperforms PET/CT in the detection of prostate cancer lesions, both in primary staging and in restaging during biochemical recurrence [34]. The gene discussed is FOLH1; the disease is prostate cancer.